These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 30882742)

  • 1. Integrated Safety Profile of a New Approved, Fully Liquid DTaP5-HB-IPV-Hib Vaccine.
    Xu J; Stek JE; Ziani E; Liu GF; Lee AW
    Pediatr Infect Dis J; 2019 Apr; 38(4):439-443. PubMed ID: 30882742
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and immunogenicity of a toddler dose following an infant series of a hexavalent diphtheria, tetanus, acellular pertussis, inactivated poliovirus, Haemophilus influenzae type b, hepatitis B vaccine administered concurrently or at separate visits with a heptavalent pneumococcal conjugate vaccine.
    Halperin SA; Tapiéro B; Dionne M; Meekison W; Diaz-Mitoma F; Zickler P; Rubin E; Embree J; Bhuyan P; Lee A; Li M; Tomovici A
    Pediatr Infect Dis J; 2014 Jan; 33(1):73-80. PubMed ID: 24346596
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunogenicity and safety of a new hexavalent vaccine (DTaP5-IPV-HB-Hib) administered in a mixed primary series schedule with a pentavalent vaccine (DTaP5-IPV-Hib).
    Martinón-Torres F; Boisnard F; Thomas S; Sadorge C; Borrow R;
    Vaccine; 2017 Jun; 35(30):3764-3772. PubMed ID: 28583305
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A prospective, observational, multi-center, post-marketing safety surveillance study of the GSK combined vaccine against diphtheria, tetanus, pertussis, poliomyelitis, and
    Elenge DM; Heo JS; Kim SS; Kim YK; Lee JH; Xavier S; Bahar E; Dos Santos G; Guignard A
    Hum Vaccin Immunother; 2024 Dec; 20(1):2406060. PubMed ID: 39376187
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunogenicity and safety of primary and booster vaccination with 2 investigational formulations of diphtheria, tetanus and Haemophilus influenzae type b antigens in a hexavalent DTPa-HBV-IPV/Hib combination vaccine in comparison with the licensed Infanrix hexa.
    Vesikari T; Rivera L; Korhonen T; Ahonen A; Cheuvart B; Hezareh M; Janssens W; Mesaros N
    Hum Vaccin Immunother; 2017 Jul; 13(7):1505-1515. PubMed ID: 28340322
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Phase III Randomized, Double-blind, Clinical Trial of an Investigational Hexavalent Vaccine Given at Two, Three, Four and Twelve Months.
    Vesikari T; Becker T; Vertruyen AF; Poschet K; Flores SA; Pagnoni MF; Xu J; Liu GF; Stek JE; Boisnard F; Thomas S; Ziani E; Lee AW
    Pediatr Infect Dis J; 2017 Feb; 36(2):209-215. PubMed ID: 27846055
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunogenicity and safety following primary and booster vaccination with a hexavalent diphtheria, tetanus, acellular pertussis, hepatitis B, inactivated poliovirus and Haemophilus influenzae type b vaccine: a randomized trial in the United States.
    Klein NP; Abu-Elyazeed R; Cheuvart B; Janssens W; Mesaros N
    Hum Vaccin Immunother; 2019; 15(4):809-821. PubMed ID: 30444673
    [TBL] [Abstract][Full Text] [Related]  

  • 8. DTaP5-IPV-Hib-HepB, a hexavalent vaccine for infants and toddlers.
    Lee AW; Jordanov E; Boisnard F; Marshall GS
    Expert Rev Vaccines; 2017 Feb; 16(2):85-92. PubMed ID: 27996332
    [TBL] [Abstract][Full Text] [Related]  

  • 9. DTaP5-HB-IPV-Hib Vaccine (Vaxelis
    Syed YY
    Paediatr Drugs; 2017 Feb; 19(1):69-80. PubMed ID: 28035545
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety profile of
    Puente Gómez I; Verheust C; Hanssens L; Dolhain J
    Expert Rev Vaccines; 2020 Aug; 19(8):771-779. PubMed ID: 32729745
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Phase III randomized, double-blind, clinical trial of an investigational hexavalent vaccine given at 2, 4, and 11-12 months.
    Silfverdal SA; Icardi G; Vesikari T; Flores SA; Pagnoni MF; Xu J; Liu GF; Stek JE; Boisnard F; Thomas S; Ziani E; Lee AW
    Vaccine; 2016 Jul; 34(33):3810-6. PubMed ID: 27288217
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunological persistence in 5 y olds previously vaccinated with hexavalent DTPa-HBV-IPV/Hib at 3, 5, and 11 months of age.
    Silfverdal SA; Assudani D; Kuriyakose S; Van Der Meeren O
    Hum Vaccin Immunother; 2014; 10(10):2795-8. PubMed ID: 25483640
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Disparate kinetics in immune response of two different
    Martinón-Torres F; Salamanca de la Cueva I; Horn M; Westerholt S; Bosis S; Meyer N; Cheuvart B; Virk N; Jakes RW; Duchenne M; Van den Steen P
    Hum Vaccin Immunother; 2024 Dec; 20(1):2342630. PubMed ID: 38687024
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Spotlight on DTPa-HBV-IPV/Hib Vaccine (Infanrix hexa).
    Dhillon S
    BioDrugs; 2010 Oct; 24(5):299-302. PubMed ID: 20795752
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety, reactogenicity and immunogenicity of a combined hexavalent tetanus, diphtheria, acellular pertussis, hepatitis B, inactivated poliovirus vaccine and Haemophilus influenzae type b conjugate vaccine, for primary immunization of infants.
    Zepp F; Knuf M; Heininger U; Jahn K; Collard A; Habermehl P; Schuerman L; Sänger R
    Vaccine; 2004 Jun; 22(17-18):2226-33. PubMed ID: 15149781
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differences by sex in IgG levels following infant and childhood vaccinations: An individual participant data meta-analysis of vaccination studies.
    Boef AGC; van der Klis FRM; Berbers GAM; Buisman AM; Sanders EAM; Kemmeren JM; van der Ende A; de Melker HE; Rots NY; Knol MJ
    Vaccine; 2018 Jan; 36(3):400-407. PubMed ID: 29223483
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized, controlled, multicenter study of the immunogenicity and safety of a fully liquid combination diphtheria-tetanus toxoid-five-component acellular pertussis (DTaP5), inactivated poliovirus (IPV), and haemophilus influenzae type b (Hib) vaccine compared with a DTaP3-IPV/Hib vaccine administered at 3, 5, and 12 months of age.
    Vesikari T; Silfverdal SA; Boisnard F; Thomas S; Mwawasi G; Reynolds D
    Clin Vaccine Immunol; 2013 Oct; 20(10):1647-53. PubMed ID: 23966556
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hepatitis B and pertussis antibodies in 4- to 5-year-old children previously vaccinated with different hexavalent vaccines.
    Vesikari T; Xu J; Johnson DR; Hall J; Marček T; Goveia MG; Acosta CJ; Lee AW
    Hum Vaccin Immunother; 2020 Apr; 16(4):867-874. PubMed ID: 31689166
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase 4, open-label study to evaluate the safety and immunogenicity of DTaP5-HBV-IPV-Hib in children previously vaccinated with DTaP2-HBV-IPV-Hib or DTaP5-HBV-IPV-Hib (V419-016).
    Guerra A; Costantino C; Martinon-Torres F; Westerholt S; Lambeth C; Chen Z; Lumley J; Marcek T; Johnson D; Wilck M
    Hum Vaccin Immunother; 2024 Dec; 20(1):2310900. PubMed ID: 38327239
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of the reactogenicity and immunogenicity of a combined diphtheria, tetanus, acellular pertussis, hepatitis B, inactivated polio (DTPa-HBV-IPV) vaccine, mixed with the Haemophilus influenzae type b (Hib) conjugate vaccine and administered as a single injection, with the DTPa-IPV/Hib and hepatitis B vaccines administered in two simultaneous injections to infants at 2, 4 and 6 months of age.
    Arístegui J; Dal-Ré R; Díez-Delgado J; Marés J; Casanovas JM; García-Corbeira P; De Frutos E; Van Esso D; Verdaguer J; De la Flor J; Moraga F; Boceta R; García-Martínez JA
    Vaccine; 2003 Sep; 21(25-26):3593-600. PubMed ID: 12922087
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.